Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

UW-SES: A new self-efficacy scale for people with disabilities.
ATX-MS-1467, An Immunotolerizing Agent, Halts Disease Progression and Reduces CNS Inflammation in Rodent Models of Multiple Sclerosis (P1.216)
A genome screen for multiple sclerosis in Italian families.
[The influence of locomotor treatment using robotic body-weight-supported treadmill training on rehabilitation outcome of patients suffering from neurological disorders].
Inhibition of Neuronal Degenerin/Epithelial Na+ Channels by the Multiple Sclerosis Drug 4-Aminopyridine.
Comprehending the inexplicable: qualitative accounts of black Caribbean and white british people severely affected by multiple sclerosis.
Materials for stem cell factories of the future.
Acute liver failure and liver transplantation in a patient with multiple sclerosis treated with interferon beta.
An Inventory of Short Term and Long Term Changes in Gene Expression Under Interferon β Treatment of Relapsing Remitting MS Patients.
Multiple sclerosis: Risk of comorbid inflammatory diseases in MS might not be genetically determined.
Mapi Pharma Receives Additional Claims for Its U.S. Patent for Glatiramer Acetate Depot for the Treatment of Multiple Sclerosis
Multiple Sclerosis: Vitamin D and calcium as environmental determinants of prevalence (A Viewpoint)
Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia.
Identifying autoantigens in demyelinating diseases: valuable clues to diagnosis and treatment?
Recurrent Nicolau syndrome associated with subcutaneous glatiramer acetate injection-a case report.
A phase II study of laquinimod in Crohn's disease.
MP2RAGE Multiple Sclerosis Magnetic Resonance Imaging at 3 T.
The value of specialty pharmaceuticals - a systematic review.
Safety Study of GNbAC1 in Multiple Sclerosis Patients
Sexual dysfunction ın multiple sclerosis: Gender differences.
Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFN-gamma production of CD8+ T cells in secondary progressive multiple sclerosis.
Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design.
Genmab collaborator GSK starts new ofatumumab Phase III study in rare skin disorder
Animal Models in Neurology: Drawbacks and Opportunities.
Progress in multiple sclerosis research in the last year.

Pages